GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
Clinical trial NCT04251117 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04251117
- Sponsor
- Geneos Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-01
- Primary completion
- 2024-11-29
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.